A rating of 62 puts Lyell Immunopharma Inc (LYEL) near the middle of the Biotechnology industry according to InvestorsObserver. Lyell Immunopharma Inc's score of 62 means it scores higher than 62% of stocks in the industry. Lyell Immunopharma Inc also received an overall rating of 57, putting it above 57% of all stocks. Biotechnology is ranked 20 out of the 148 industries.
LYEL has an Overall Score of 57. Find out what this means to you and get the rest of the rankings on LYEL!
Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.
What's Happening With Lyell Immunopharma Inc Stock Today?
Lyell Immunopharma Inc (LYEL) stock is lower by -3.32% while the S&P 500 has risen 0.14% as of 2:56 PM on Friday, Jan 13. LYEL is down -$0.11 from the previous closing price of $3.31 on volume of 377,416 shares. Over the past year the S&P 500 has fallen -14.39% while LYEL is down -47.71%. LYEL lost -$1.04 per share the over the last 12 months.
Click Here to get the full Stock Report for Lyell Immunopharma Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
